Pharma & Bio
Business·Industry
L&K BIOMED CO., LTD.: “Amended Global Distribution Agreement for Spinal Implants… Simultaneously in Discussions with Other Global Companies”
“There have been changes to the distribution agreement with a global company that we have been pursuing. While discussions regarding a distribution agreement in the U.S. have been suspended due to a s…
Lifestyle
"From Anchors to Surgical Instruments"... OSTEONIC Co., Ltd. Sees Another Jump in Earnings This Year Thanks to Its Package Strategy
OSTEONIC Co., Ltd.(226400)is set to achieve a quantum leap in performance through a “package strategy” that combines surgical instruments with its SportsMedicine implants. With the “Suture Passer”—a s…
Lifestyle
Cellbion Co., Ltd Begins Clinical Trial Combining Keytruda with Merck... Company Valuation Set to Rise
#Cellbion Co., Ltd, a company specializing in radiopharmaceuticals (RPT), is expected to see its corporate value reassessed as it moves to commercialize a prostate cancer treatment and enhance the val…
Lifestyle
Investors Ask... What Is the Post-IPO Growth Roadmap and What Are the Risk Factors? [In-Depth Look at Ingenia ③]
Ingenia Therapeutics is set to receive milestone payments totaling 50 billion won from Merck by the end of this year. In addition, Edaily’s premium pharma and biotech content platform, PharmEdaily, ha…
Lifestyle
The Key Technology Merck Has Set Its Sights On... Targeting a $5 Billion Market Value [In-Depth Look at Ingenia, Part 2]
The driving force behind global pharmaceutical and biotech companies’ large-scale investment in Ingenia Therapeutics’ technology lies in “LCIDEC” (Ligand Capture, Internalization, Degradation in EC), …
Lifestyle
U.S.-Based Biotech Company Sets to Become a Successful KOSDAQ Listing [In-Depth Look at Ingenia, Part 1]
Ingenia Therapeutics (Ingenia), an innovative antibody drug development company headquartered in Boston, U.S., has passed the Korea Exchange’s preliminary review for a KOSDAQ listing and is now moving…
Lifestyle
Choi Seok-geun, CEO of EyeGene,Inc: “The Nation’s Only Combination of mRNA and GCT Technologies Will Accelerate the Path to a ‘Profitable Biotech Company’”
"We will break free from the limitations of a biotech venture that remains confined to research and development (R&D). By progressively commercializing our proven revenue-generating pipeline—including…
Lifestyle
Patient Monitoring Market: A Silent Battle... SEERS’ Strategy to Expand into Neurology
As competition in the domestic patient monitoring market intensifies, SEERS TECHNOLOGY(458870)is seeking to differentiate itself by expanding its market presence based on clinical data. Rather than en…
Technology
Hyundai pharm Rises with Every Presidential Remark… Beyond Policy Themes, Earnings and Structural Improvements Are Accelerating
Hyundai pharm(004310)The company has been drawing market attention every time the Lee Jae-myung administration makes statements regarding pharmaceutical policy. Following a sharp rise in its stock pri…
Technology
[K-Bio Pulse] Biotech Stocks Defy 'Black Tuesday' as MedPacto Soars, Bioinfra Faces Deadline
Despite the “Black Tuesday” sell-off on July 28, several biotech stocks bucked the broader market trend. As the KOSDAQ tumbled, Cellid, Bioinfra, and MedPacto all hit the daily upper limit. MedPacto g…